Degree of Cyclooxygenase-2 Inhibition Modulates Blood Pressure Response to Celecoxib and Naproxen

- 3 Katherine N. Theken, PharmD, PhD;^{1,2*} Soumita Ghosh, PhD;¹ Carsten Skarke, MD;^{1,3} Susanne
- Fries, MD;¹ Nicholas F. Lahens, PhD;¹ Dimitra Sarantopoulou, MS;^{1,4} Gregory R. Grant, PhD;^{1,5}
- 5 Garret A. FitzGerald, MD;^{1,3} Tilo Grosser, MD^{1,3,6*}
- 6 ¹ Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University
- of Pennsylvania, Philadelphia, PA, United States
- 8 ² Department of Oral and Maxillofacial Surgery and Pharmacology, School of Dental Medicine,
- University of Pennsylvania, Philadelphia, PA, United States
- ³ Department of Medicine, University of Pennsylvania, Philadelphia, PA, United States
- 11 ⁴ Current address: National Institute on Aging, National Institutes of Health, Baltimore, MD,
- United States
- 13 ⁵ Department of Genetics, University of Pennsylvania, Philadelphia, PA, United States
- 14 ⁶ Department of Translational Pharmacology, EWL School of Medicine, Bielefeld University,
- Bielefeld, Germany
- **Short Title:** COX2 Inhibition and Hypertensive Effects of NSAIDs

***Corresponding Authors:**

- Katherine N. Theken, PharmD, PhD
- Department of Oral and Maxillofacial Surgery and Pharmacology
- School of Dental Medicine, University of Pennsylvania
- 21 $240 S 40^{th} St$
- Room 531 Levy
- Philadelphia, PA 19104
- Phone: +1 215 898-7470
- Email: ktheken@pennmedicine.upenn.edu
-
- Tilo Grosser, MD
- Department of Translational Pharmacology
- EWL School of Medicine
- Bielefeld University
- Universitätsstrasse 25
- Bielefeld, Germany
-
- Phone: +49 521 106-86800
- Email: tilo.grosser@uni-bielefeld.de
-
- **Word Count:** 4701

Abstract:

 Background: Non-steroidal anti-inflammatory drugs (NSAIDs) increase the risk of adverse cardiovascular events via suppression of cyclooxygenase (COX)-2-derived prostacyclin (PGI2) formation in heart, vasculature, and kidney. The Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION) trial and other large clinical studies compared the cardiovascular risk of traditional NSAIDs (i.e. naproxen), which inhibit both COX isozymes, with NSAIDs selective for COX-2 (i.e. celecoxib). However, whether pharmacologically equipotent doses were used - that is, whether a similar degree of COX-2 inhibition was achieved - was not considered. We compared drug target inhibition and blood pressure response to celecoxib at the dose used by most patients in PRECISION with the lowest recommended naproxen dose for osteoarthritis, which is lower than the dose used in PRECISION.

 Methods: Sixteen healthy participants (19-61 years) were treated with celecoxib (100 mg every 12h), naproxen (250 mg every 12h), or placebo administered twice daily for seven days in a double-blind, crossover design randomized by order. On Day 7 when drug levels had reached steady state, the degree of COX inhibition was assessed *ex vivo* and *in vivo*. Ambulatory blood pressure was measured throughout the final 12h dosing interval.

Results: Both NSAIDs inhibited COX-2 activity relative to placebo, but naproxen inhibited

56 COX-2 activity to a greater degree $(62.9\pm21.7%)$ than celecoxib $(35.7\pm25.2%)$; p<0.05).

Similarly, naproxen treatment inhibited PGI² formation *in vivo* (48.0±24.9%) to a greater degree

than celecoxib (26.7±24.6%; p<0.05). Naproxen significantly increased blood pressure

compared to celecoxib (differences in least-square means of mean arterial pressure: 2.5 mm Hg

(95% CI: 1.5, 3.5); systolic blood pressure: 4.0 mm Hg (95% CI: 2.9, 5.1); diastolic blood

pressure: 1.8 mm Hg (95% CI: 0.8, 2.8); p<0.05 for all). The difference in systolic blood

pressure relative to placebo was associated with the degree of COX-2 inhibition (p<0.05).

 Conclusions: Celecoxib 200 mg/day inhibited COX-2 activity to a lesser degree than naproxen 500 mg/day, resulting in a less pronounced blood pressure increase. While the PRECISION trial concluded the non-inferiority of celecoxib regarding cardiovascular risk, this is based on a comparison of doses that are not equipotent.

- ClinicalTrials.gov identifier: NCT02502006 (https://clinicaltrials.gov/study/NCT02502006)
-

69 **Clinical Perspective**

- 70 Naproxen 250 mg twice a day inhibited COX-2 activity to a greater degree than 71 celecoxib 100 mg twice a day.
- 72 The degree of COX-2 inhibition was associated with the increase in systolic blood 73 pressure with NSAID treatment relative to placebo.
- 74 Dose and its pharmacological potency achieved *in vivo* should be considered when 75 evaluating the relative cardiovascular safety of COX-2-selective vs. non-selective 76 NSAIDs.

77 **Introduction**

78 Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most commonly used 79 medications worldwide and the opioid crisis has placed a new emphasis on their use.^{1,2} 80 Approximately 20% of adults in the United States receive at least one NSAID prescription per 81 year³, and 12% of adults in the United States reported using NSAIDs chronically, i.e. more than 82 three times weekly for more than three months. 4 Consumption of NSAIDs in individuals at risk 83 for musculoskeletal injuries is even more common.⁵⁻⁷ Given the high prevalence of chronic pain 84 in the United States – more than 100 million Americans suffer from chronic pain⁸ – NSAIDs are 85 an important non-addictive option for pain relief. Optimizing NSAID therapy is one strategy to 86 address the current opioid crisis,² and rates of NSAID use have increased in recent years as 87 opioid prescriptions have declined.⁹ Although they lack the addictive potential of opioids, 88 NSAIDs have the potential to cause serious, and in some cases, life-threatening adverse 89 events, including gastrointestinal bleeding, renal dysfunction, hypertension, and thrombotic 90 cardiovascular events.¹⁰ Undetected blood pressure (BP) increases that may impact 91 Cardiovascular morbidity and mortality at the population level are a particular concern.¹¹

92 NSAIDs exert their analgesic and anti-inflammatory effects via inhibition of 93 cyclooxygenase (COX)-1 and/or COX-2, enzymes that catalyze the first committed step in 94 prostaglandin (PG) synthesis. PGs produce a diverse array of biologic effects via activation of 95 prostanoid receptors and play important roles in a variety of pathologic and homeostatic 96 processes.¹² The risk of thrombotic events associated with the use of NSAIDs, particularly those 97 selective for COX-2, is mediated via suppression of COX-2-derived prostacyclin $(PGI₂)$ 98 formation in endothelial and vascular smooth muscle cells.^{13,14} PGI₂ possesses potent anti-99 thrombotic and vasodilatory effects, and thus acts as a general inhibitor of platelet activation *in* 100 vivo.¹² Non-selective NSAIDs also inhibit COX-2 in the vasculature, but the associated risk of 101 thrombosis is mitigated to some extent by inhibition of formation of thromboxane A_2 (TxA₂), a 102 COX-1-derived PG released by activated platelets that promotes platelet activation and 103 aggregation.^{10,15} In addition to their effects on vascular PG production, NSAIDs inhibit renal PG 104 formation, resulting in sodium retention and BP increases, which may further augment 105 cardiovascular risk. $10,15,16$

 One of the largest (N=24,081) outcome studies to date, the Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen trial (PRECISION), compared the safety of the COX-2 selective NSAID, celecoxib (100 to 200 mg twice a day) , and two traditional NSAIDs, naproxen (375 to 500 mg twice a day) and ibuprofen (600 to 800 mg

 three times a day), in osteoarthritis (90%) and rheumatoid arthritis (10%) patients. PRECISION concluded that the cardiovascular safety of moderate doses of celecoxib (average dose: 209±37 mg/day) was noninferior to naproxen (average dose: 852±103 mg/day) or ibuprofen 113 (average dose: 2045 ± 246 mg/day).¹⁷ However, a secondary on-treatment analysis of PRECISION showed a lower risk of cardiorenal events in the celecoxib group than the ibuprofen 115 and naproxen groups.¹⁸ Similarly, a pre-specified substudy (PRECISION-ABPM) reported that the percentage of patients with normal baseline blood pressure who developed hypertension was significantly greater in patients treated with naproxen (19%) or ibuprofen (23%), than with 118 celecoxib (10%).¹⁹ However, the degree of COX-2 inhibition attained has never been assessed in clinical outcome trials, and thus it is unknown whether the doses employed in PRECISION were equipotent. Here, we compared the pharmacologic potency of celecoxib, 200 mg/day (the highest dose allowed for osteoarthritis and roughly the average daily dose in PRECISION), with naproxen, 500 mg/day (the lowest recommended dose for osteoarthritis and approximately 40% lower than the average daily dose in PRECISION), and how this relates to blood pressure response to NSAIDs in a highly controlled study in apparently healthy volunteers.

Methods

Participants

 Men and women (≥18 years of age) who were in good health based on medical history, physical examination, vital signs, and laboratory tests were enrolled. Participants were excluded if they were pregnant or nursing a child, smoked or used nicotine-containing products, 131 were obese (body mass index (BMI) > 30 kg/m²), had a history of significant cardiovascular, gastrointestinal, renal, hepatic, respiratory, immune, endocrine, hematologic, or neurological disease, a history of cancer within the last 5 years, or a coagulation or bleeding disorder, were sensitive or allergic to celecoxib, naproxen, aspirin, or other NSAIDs, or had used NSAIDs (including acetaminophen), dietary or herbal supplements containing salicylates, Vitamin E, fish oil, or any other herbal supplements, within 14 days of study drug administration.

Study procedures

 The study protocol was approved by the University of Pennsylvania Institutional Review Board (IRB#820715; ClinicalTrials.gov: NCT02502006), and all participants provided informed consent. The study was a randomized, double-blind, three-way crossover study comparing the degree of COX inhibition and the blood pressure response at steady state following treatment

 with celecoxib (100 mg twice daily), naproxen (250 mg twice daily), or placebo (twice daily) for 7 days. Prior to beginning treatment, all participants attended a screening visit to obtain a complete medical history and confirm eligibility. They were asked to abstain from analgesics, including products containing NSAIDs (including aspirin and acetaminophen), high dose vitamins, and nutritional supplements until study completion.

 On the first day of each treatment phase, baseline blood and urine samples were collected, and participants were given a blisterpack with blinded study medication to be taken by mouth twice daily on an outpatient basis. Study medication was blinded by over-encapsulation by the University of Pennsylvania Investigational Drug Service. On the morning of day 7, participants returned to clinic for a 12-hour visit for pharmacokinetic-pharmacodynamic (PK-PD) sampling. An ambulatory blood pressure monitor (ABPM, Spacelabs 90207), which recorded blood pressure every 15 minutes throughout the study visit, was placed on the non-dominant upper arm. Blood and urine samples were collected (T=0), and the final dose of study medication was administered. Additional samples were collected 0.5 (blood only), 1, 2, 4, 8, and 12 hours after study medication administration. Participants were discharged after the 12- hour sample collection. These study visits were repeated for the next two treatment phases, with a washout period of at least 2 weeks between each treatment phase.

 Study data were collected and managed using REDCap (Research Electronic Data 160 Capture) hosted at the University of Pennsylvania Perelman School of Medicine.^{20,21}

Quantification of COX activity and plasma drug concentrations

162 COX-1 activity *ex vivo* was evaluated by quantifying serum thromboxane B₂ levels, as 163 previously described.²² Briefly, whole blood was collected into vacuum tubes containing clot activator and incubated in a water bath at 37˚C for 1 hour. Serum was separated by centrifugation and stored at -80˚C until analysis by liquid chromatography-tandem mass spectrometry (LC-MS/MS).

167 COX-2 activity ex vivo was evaluated by quantifying plasma PGE₂ levels following 168 lipopolysaccharide (LPS) stimulation in whole blood, as previously described.²³ Briefly, heparinized whole blood was treated with aspirin (1 mM) and incubated at room temperature for 15 minutes. LPS (E. coli, serotype O111:B4, 10 µg/ml whole blood) was added, and the sample was incubated in a water bath at 37˚C for 24 hours. Plasma was separated by centrifugation and stored at -80˚C until analysis by LC-MS/MS.

 COX activity *in vivo* was determined by quantification of urinary prostanoid metabolites 174 by LC-MS/MS as previously described.¹⁴ Systemic production of $PGI₂$, $PGE₂$, $PGD₂$, and

175 thromboxane (Tx) A_2 was determined by quantifying their major urinary metabolites: 2,3-dinor 6-176 keto-PGF_{1α} (PGIM), 7-hydroxy-5,11-diketotetranorprostane-1,16-dioic acid (PGEM), 11,15-177 dioxo-9α-hydroxy-2,3,4,5-tetranorprostan-1,20-dioic acid (PGDM), and 2,3-dinor TxB₂ (TxM), respectively. Results were normalized to urinary creatinine measured by LC-MS/MS.

 Plasma concentrations of celecoxib and naproxen were quantified by LC-MS/MS as 180 previously described.²⁴

Statistical analysis

 Measurements of COX activity *ex vivo* and urinary PG metabolite levels were normalized to the mean value during the placebo phase for each subject to calculate the percent of COX inhibition relative to placebo. Area-under-the-curve from T=0 to T=12 hours (AUC) was calculated as a measure of the degree of COX inhibition throughout the dosing interval. The degree of COX inhibition was compared by paired t-test. The effect of treatment on COX 187 activity and ABP over time was analyzed by linear mixed effect modeling using the lme4 R 188 package,²⁵ including time and treatment as main effects and participant as a random effect. The relationship between change in SBP and COX inhibition over the 12-hour dosing interval was evaluated by linear regression. P<0.05 was considered statistically significant. Statistical analyses were performed in R (version 4.3.1).

Results

 The study cohort included 16 healthy adults (9 men, 7 women) with a mean age of 34.7±13.4 years. Baseline demographic and clinical characteristics are shown in Table 1. Biochemical measures were evaluated in all participants. One participant was excluded from ABP analysis due to ABPM malfunction and incomplete data.

 Naproxen 250 mg twice daily inhibited COX-1 activity and COX-2 activity *ex vivo* by 95.3±4.4% and 62.9±21.7%, respectively, while celecoxib 100 mg twice daily had minimal effects on COX-1 activity *ex vivo* and inhibited COX-2 activity *ex vivo* by 35.7±25.2% over the 12-hour dosing interval (Figure 1). Similar results were observed for COX activity *in vivo*, assessed by urinary PG metabolite concentrations. TxM (an index of COX-1 activity*)* was inhibited by 68.2±18.7% with naproxen treatment and 8.9±35.7% with celecoxib treatment. PGIM (an index of COX-2 activity *in vivo*) was inhibited by 48.0±24.9% with naproxen treatment and 26.7±24.6% with celecoxib treatment. With all functional parameters, the degree of COX inhibition was significantly greater with naproxen treatment than celecoxib treatment (p<0.05). 207 The maximum plasma concentration (C_{max}) of naproxen was 228 \pm 45.1 µM, and the time to

208 maximum plasma concentration (t_{max}) was 1.8±1.2 h after administration. For celecoxib, C_{max} 209 was 1.28 \pm 0.55 µM, and t_{max} was 2.3 \pm 1.2 h.

210 During the placebo phase, average MAP, SBP, and DBP were 89.7±8.7 mmHg, 211 124.1±11.2 mm Hg, and 73.3±8.7 mm Hg, respectively. NSAID treatment affected MAP and SBP over the 12-hour dosing interval (Figure 2). Naproxen treatment significantly increased MAP (Difference in LS means: 3.1 mm Hg (95% CI: 2.1, 4.1); p<0.05), SBP (Difference in LS means: 2.9 mm Hg (95% CI: 1.8, 4.0); p<0.05) and DBP (Difference in LS means: 3.2 mm Hg (95% CI: 2.2, 4.2); p<0.05) relative to placebo. In contrast, celecoxib treatment did not affect MAP (Difference in LS means: 0.6 mm Hg (95% CI: -0.3, 1.6); p=0.28), but significantly decreased SBP (Difference in LS means: -1.1 mm Hg (95% CI: -2.2, 0.04); p<0.05) and increased DBP (Difference in LS means: 1.4 mm Hg (95% CI: 0.4, 2.4); p<0.05) relative to placebo. Compared to celecoxib, naproxen significantly increased MAP (Difference in LS means: 2.5 mm Hg (95% CI: 1.5, 3.5); p<0.05), SBP (Difference in LS means: 4.0 mm Hg (95% CI: 2.9, 5.1); p<0.05), and DBP (Difference in LS means: 1.8 mm Hg (95% CI: 0.8, 2.8); p<0.05).

 Linear regression was performed to determine whether the degree of COX-1 or COX-2 inhibition *ex vivo* predicted the difference in SBP with NSAID treatment relative to placebo (Figure 3). COX-2 inhibition *ex vivo* was a predictor of difference in SBP (β=-10.38, 95% 226 confidence interval=-19.27 to -1.482, R^2 =0.1694, $F(1,28)$ =5.710, p=0.0238), but COX-1 inhibition *ex vivo* was not significantly associated with difference in SBP (β=-2.194, 95% 228 confidence interval=-6.068 to 1.680, R^2 =0.04587, F(1,28)=1.346, p=0.2558).

Discussion

231 Given the high prevalence of chronic pain in the United States, 26 NSAIDs are an 232 important non-addictive option for pain relief.² Currently, it is recommended that NSAIDs be avoided or used only for a limited duration at the lowest possible dose in patients considered at 234 high cardiovascular risk.²⁷ As COX-2 inhibition mechanistically underlies the cardiovascular risk, a key question remains whether differences in the cardiovascular safety profile exist between traditional NSAIDs (i.e. naproxen) which inhibit both COX-1 and COX-2, and selective 237 inhibitors of COX-2 (i.e. celecoxib).²⁸ The largest comparator trial to address this question, PRECISION, indicated that celecoxib is noninferior to naproxen and ibuprofen with regard to 239 cardiovascular risk.¹⁷ Importantly, the dose of celecoxib was limited to 200 mg/day in osteoarthritis patients enrolled in PRECISION, which made up the vast majority of the study

 population. Limiting the dose in osteoarthritis patients had been a regulatory response to the cardiovascular hazard detected in previous randomized controlled trials. Although the pharmacological potency of celecoxib measured with isolated COX-2 enzyme or cellular 244 preparations *in vitro* is higher than that of naproxen,²⁹ here we demonstrate that the average daily dose of celecoxib used in the PRECISION trial inhibited COX-2 activity *in vivo* to a lesser degree than a low dose of naproxen and that this impacted the blood pressure response to NSAID treatment. Our results underscore the importance of considering dose and pharmacoequivalence *in vivo* in comparisons of safety among drugs of the same class.

 Only a small number of clinical trials have prospectively assessed the effects of COX inhibition on BP control. Based on these studies, increases of 3-5 mmHg in SBP can be 251 expected.¹⁶ In our cohort, naproxen treatment increased SBP relative to placebo (2.9 mm Hg (95% CI: 1.8,4.0)) to a greater extent than celecoxib treatment (-1.1 mm Hg (95% CI: -2.2,- 0.04)) over the 12-hour dosing interval. This difference is similar to what was observed in PRECISION-ABPM, where the change in SBP from baseline after 4 months of treatment was - 0.18±9.400 mm Hg among celecoxib-treated patients and 1.91±9.796 mm Hg among naproxen-256 treated patients.¹⁹ Notably, we observed that the difference in SBP was associated with the degree of COX-2 inhibition on NSAID treatment, consistent with the inhibition of COX-2- mediated PGI² formation as the primary mechanism underlying the increased cardiovascular risk associated with NSAID use.

 Although naproxen increased SBP to a greater extent than celecoxib in our study cohort, the blood pressure response to NSAID treatment was heterogeneous among individual patients. The effects of COX inhibition on blood pressure control are complex, which may contribute to 263 the variable occurrence of hypertension on NSAIDs.^{10,15,16,30} In the renal cortex, the production 264 of vasodilatory PGE_2 and PGI_2 maintain the patency of adjacent afferent arterioles,^{16,31} and COX-2 expression in renal medullary interstitial cells play an important role in the adaptive 266 regulation of blood pressure in response to high salt diet and dehydration.³²⁻³⁴ COX inhibition in these regions of the kidney contributes to the decline in glomerular filtration rate and elevations in blood pressure observed in patients who take NSAIDs. However, dynamic expression of COX-2 in the macula densa system is a component of the tubuloglomerular feedback 270 mechanism which promotes renin release. $35-37$ Inhibition of COX-2 in these cells would counteract the hypertensive effects of renin-angiotensin system activation. Thus, the effect of NSAID treatment on blood pressure reflects the complex interplay among these regulatory systems. Interestingly, we observed that an individual participant's response was similar to both drugs, suggesting that patient-specific factors may contribute to interindividual heterogeneity in

 the response to NSAIDs. Future studies are necessary to elucidate the factors that contribute to an individual patient's risk of hypertension and other cardiovascular adverse effects with NSAID treatment.

 There are limitations to our study. The small sample size limits our ability to comprehensively investigate the factors that contribute to the blood pressure response to NSAIDs. The study cohort included only healthy adults, most of whom were relatively young. Although this limits potential confounding due to effects of age and comorbidities, it precludes interrogation of the influence of these factors on the blood pressure response to NSAID treatment. Finally, we compared only one dose level of naproxen and celecoxib, which limits our ability to extrapolate our results to higher doses or other NSAIDs. Despite these limitations, our results provide mechanistic insight into the outcome of PRECISION.

286 In conclusion, our results demonstrate that naproxen 500 mg/day inhibits COX-2 activity to a greater degree than celecoxib 200 mg/day and that the degree of COX-2 inhibition is associated with the blood pressure response to NSAID treatment. While PRECISION concluded non-inferiority of celecoxib compared to naproxen with regard to cardiovascular risk, this is based on a comparison of doses that are not equipotent.

292 **Table 1.** Baseline characteristics of study participants.

293

295 **Figures**

296 **Figure 1.** Comparison of (A) COX-1 inhibition *ex vivo* and (B) *in vivo* and (C) COX-2 inhibition

- 297 *ex vivo* and (D) *in vivo* by treatment. Plasma concentrations of (E) celecoxib and (F) naproxen
- 298 over time. Dosing occurred at 8:00 AM \pm 15 min. Data are shown as mean \pm SEM. *p<0.05

301 **Figure 2.** Comparison of (A) SBP, (B) DBP, and (C) MAP over 12-hour dosing interval by 302 treatment. Data are shown as mean \pm SEM. (D) Change in SBP relative to placebo with 303 celecoxib and naproxen treatment. Dosing occurred at 8:00 AM ± 15 min. *p<0.05

304

Celecoxib **D** Naproxen \bullet

Sources of Funding

 Research reported in this publication was supported by a Translational Medicine and Therapeutics Postdoctoral Fellowship from the PhRMA Foundation, and funding from the National Heart, Lung, and the Blood Institute (HL117798) and National Center for Advancing Translational Sciences of the National Institutes of Health (UL1TR001878). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Acknowledgements

- Dr. FitzGerald is the McNeil Professor of Translational Medicine and Therapeutics and held a
- Merit Award from the American Heart Association. C.S. is the Robert L. McNeil Jr. Fellow in
- Translational Medicine and Therapeutics.

Disclosures

K.N.T., S.G., C.S., S.F., N.F.L., D.S., G.R.G., G.A.F., and T.G. have nothing to disclose.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.05.30.24308244;](https://doi.org/10.1101/2024.05.30.24308244) this version posted May 31, 2024. The copyright holder for this preprint

References

 1. In: Phillips JK, Ford MA, Bonnie RJ, eds. *Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use*. Washington (DC); 2017. 2. Grosser T, Woolf CJ, FitzGerald GA. Time for nonaddictive relief of pain. *Science*. 2017;355:1026- 1027. doi: 10.1126/science.aan0088 3. Stagnitti MN. Trends in Outpatient Prescription Analgesics Utilization and Expenditures for the U.S. Civilian Noninstitutionalized Population, 1996 and 2006. Medical Expenditure Panel Survey. https://meps.ahrq.gov/data_files/publications/st235/stat235.shtml. 2009. Accessed 1/5/2024. 4. Zhou Y, Boudreau DM, Freedman AN. Trends in the use of aspirin and nonsteroidal anti- inflammatory drugs in the general U.S. population. *Pharmacoepidemiology and drug safety*. 2014;23:43-50. doi: 10.1002/pds.3463 5. Gorski T, Cadore EL, Pinto SS, da Silva EM, Correa CS, Beltrami FG, Kruel LF. Use of NSAIDs in triathletes: prevalence, level of awareness and reasons for use. *British journal of sports medicine*. 2011;45:85-90. doi: 10.1136/bjsm.2009.062166 6. Kuster M, Renner B, Oppel P, Niederweis U, Brune K. Consumption of analgesics before a marathon and the incidence of cardiovascular, gastrointestinal and renal problems: a cohort study. *BMJ open*. 2013;3. doi: 10.1136/bmjopen-2012-002090 7. Walker LA, Zambraski EJ, Williams RF. Widespread Use of Prescription Nonsteroidal Anti- Inflammatory Drugs Among U.S. Army Active Duty Soldiers. *Military medicine*. 2017;182:e1709- e1712. doi: 10.7205/MILMED-D-16-00183 8. Institute of Medicine (US) Committee on Advancing Pain Research C, and Education. . Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. 2011. doi: NBK91497 [bookaccession] 9. Keshwani S, Smith SM, Brown J, Lo-Ciganic WH, Yang S, Smolinski NE, Hincapie-Castillo JM. Trends in Prescribing of Non-steroidal Anti-inflammatory Medications in the US Ambulatory Care Setting From 2006 to 2016. *The journal of pain : official journal of the American Pain Society*. 2023. doi: 10.1016/j.jpain.2023.06.008 10. Grosser T, Yu Y, Fitzgerald GA. Emotion recollected in tranquility: lessons learned from the COX- 2 saga. *Annu Rev Med*. 2010;61:17-33. doi: 10.1146/annurev-med-011209-153129 11. Krum H, Swergold G, Gammaitoni A, Peloso PM, Smugar SS, Curtis SP, Brater DC, Wang H, Kaur A, Laine L, et al. Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugs. *Cardiovasc Ther*. 2012;30:342-350. doi: 10.1111/j.1755- 5922.2011.00283.x 12. Smyth EM, Grosser T, Wang M, Yu Y, FitzGerald GA. Prostanoids in health and disease. *J Lipid Res*. 2009;50 Suppl:S423-428. doi: 10.1194/jlr.R800094-JLR200 13. Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T, Lawson JA, FitzGerald GA. Role of prostacyclin in the cardiovascular response to thromboxane A2. *Science*. 2002;296:539-541. doi: 10.1126/science.1068711 14. Yu Y, Ricciotti E, Scalia R, Tang SY, Grant G, Yu Z, Landesberg G, Crichton I, Wu W, Pure E, et al. Vascular COX-2 modulates blood pressure and thrombosis in mice. *Sci Transl Med*. 2012;4:132ra154. doi: 10.1126/scitranslmed.3003787 15. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. *J Clin Invest*. 2006;116:4-15. doi: 10.1172/JCI27291 16. Catella-Lawson F, McAdam B, Morrison BW, Kapoor S, Kujubu D, Antes L, Lasseter KC, Quan H, Gertz BJ, FitzGerald GA. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. *J Pharmacol Exp Ther*. 1999;289:735-741.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.05.30.24308244;](https://doi.org/10.1101/2024.05.30.24308244) this version posted May 31, 2024. The copyright holder for this preprint

 17. Nissen SE, Yeomans ND, Solomon DH, Luscher TF, Libby P, Husni ME, Graham DY, Borer JS, Wisniewski LM, Wolski KE, et al. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. *N Engl J Med*. 2016;375:2519-2529. doi: 10.1056/NEJMoa1611593 18. Obeid S, Libby P, Husni E, Wang Q, Wisniewski LM, Davey DA, Wolski KE, Xia F, Bao W, Walker C, et al. Cardiorenal risk of celecoxib compared with naproxen or ibuprofen in arthritis patients: insights from the PRECISION trial. *Eur Heart J Cardiovasc Pharmacother*. 2022;8:611-621. doi: 10.1093/ehjcvp/pvac015 19. Ruschitzka F, Borer JS, Krum H, Flammer AJ, Yeomans ND, Libby P, Luscher TF, Solomon DH, Husni ME, Graham DY, et al. Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial. *European heart journal*. 2017. doi: 10.1093/eurheartj/ehx508 20. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform*. 2009;42:377-381. doi: 10.1016/j.jbi.2008.08.010 21. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, McLeod L, Delacqua G, Delacqua F, Kirby J, et al. The REDCap consortium: Building an international community of software platform partners. *J Biomed Inform*. 2019;95:103208. doi: 10.1016/j.jbi.2019.103208 22. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. *J Clin Invest*. 1982;69:1366-1372. 23. Panara MR, Renda G, Sciulli MG, Santini G, Di Giamberardino M, Rotondo MT, Tacconelli S, Seta F, Patrono C, Patrignani P. Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. *J Pharmacol Exp Ther*. 1999;290:276-280. 24. Li X, Fries S, Li R, Lawson JA, Propert KJ, Diamond SL, Blair IA, FitzGerald GA, Grosser T. Differential impairment of aspirin-dependent platelet cyclooxygenase acetylation by nonsteroidal antiinflammatory drugs. *Proc Natl Acad Sci U S A*. 2014;111:16830-16835. doi: 10.1073/pnas.1406997111 25. Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using lme4. *Journal of Statistical Software*. 2015;67:1 - 48. doi: 10.18637/jss.v067.i01 26. Institute of Medicine (U.S.). Committee on Advancing Pain Research Care and Education. *Relieving pain in America : a blueprint for transforming prevention, care, education, and research*. Washington, D.C.: National Academies Press; 2011. 27. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. *Circulation*. 2007;115:1634-1642. doi: 10.1161/CIRCULATIONAHA.106.181424 28. Grosser T, Ricciotti E, FitzGerald GA. The Cardiovascular Pharmacology of Nonsteroidal Anti- inflammatory Drugs. *Trends Pharmacol Sci*. 2017;38:(in press). 29. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. *Proc Natl Acad Sci U S A*. 1999;96:7563-7568. 30. Snowden S, Nelson R. The effects of nonsteroidal anti-inflammatory drugs on blood pressure in hypertensive patients. *Cardiol Rev*. 2011;19:184-191. doi: 10.1097/CRD.0b013e31821ddcf4 31. Terragno NA, Terragno DA, McGiff JC. Contribution of prostaglandins to the renal circulation in conscious, anesthetized, and laparotomized dogs. *Circulation research*. 1977;40:590-595. 32. Perazella MA, Tray K. Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs. *Am J Med*. 2001;111:64-67.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.05.30.24308244;](https://doi.org/10.1101/2024.05.30.24308244) this version posted May 31, 2024. The copyright holder for this preprint

- 33. Qi Z, Hao CM, Langenbach RI, Breyer RM, Redha R, Morrow JD, Breyer MD. Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. *J Clin Invest*. 2002;110:61-69.
- 34. Zewde T, Mattson DL. Inhibition of cyclooxygenase-2 in the rat renal medulla leads to sodium-sensitive hypertension. *Hypertension*. 2004;44:424-428.
- 35. FitzGerald GA, Hossmann V, Hummerich W, Konrads A. The renin--kallikrein--prostaglandin
- system: plasma active and inactive renin and urinary kallikrein during prostacyclin infusion in man. *Prostaglandins Med*. 1980;5:445-456.
- 36. Peti-Peterdi J, Komlosi P, Fuson AL, Guan Y, Schneider A, Qi Z, Redha R, Rosivall L, Breyer MD, Bell PD. Luminal NaCl delivery regulates basolateral PGE2 release from macula densa cells. *J Clin Invest*. 2003;112:76-82.
- 37. Stichtenoth DO, Marhauer V, Tsikas D, Gutzki FM, Frolich JC. Effects of specific COX-2-inhibition on renin release and renal and systemic prostanoid synthesis in healthy volunteers. *Kidney Int*. 2005;68:2197-2207.